Ondansetron Augmentation in Treatment-resistant OCD
Sponsored by Institute of Neuroscience, Florence, Italy
About this trial
Last updated 14 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 15 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- a diagnosis of OCD established by clinical interview with a licensed psychiatrist;
- a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale
- a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose
Exclusion Criteria
- diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, current substance dependence or abuse, and current major depressive episode preceding the onset of obsessive compulsive disorder
- undergoing concomitant behavior therapy
- or having significant cardiovascular, hepatic, renal or pulmonary diseases